Estrogen Patch Shortages Hit Patients Amid Rising Demand

Patients and healthcare providers are experiencing shortages and delays in filling prescriptions for transdermal estrogen patches, a common form of hormone therapy for menopause symptoms. This critical issue is directly linked to a notable rise in demand for the treatment.

Demand Soars Following FDA Warning Removal

The demand for hormone therapy has consistently grown over recent years. A key factor in this increase was the Food and Drug Administration (FDA)'s decision last year to remove the "black box warning" from estrogen products.

This warning, the FDA's most stringent safety label, had been applied in the early 2000s after the Women's Health Initiative study indicated higher risks of heart attacks, strokes, and pulmonary embolism associated with hormone therapy.

Advancements in Treatment Methods Boost Safety and Use

The FDA's removal of the warning reflects evolving evidence on safety, alongside the development of newer hormone therapy delivery methods, and alternative product combinations.

A significant development contributing to increased demand is the use of transdermal estrogen patches or gels. Unlike the oral estrogen pills used in the earlier study, these transdermal methods deliver the hormone through the skin, bypassing metabolism by the liver. This transdermal application is associated with a reduced risk of blood clots, further contributing to its increased use and popularity.

Supply Chain Challenges Emerge

CVS has confirmed that manufacturers are struggling to provide adequate supplies of various estrogen products. Amneal Pharmaceuticals, a producer of estradiol patches, has acknowledged the "significant increase in demand" following the FDA's warning removal and is actively working to boost production.

Patients have reported difficulties in obtaining their prescriptions, with some resorting to online pharmacies to ensure a consistent supply.